血管性认知障碍患者MicroRNA-140-5p和胱抑素- c的表达及其临床价值

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-05-22 DOI:10.1080/17520363.2025.2468150

Huiyan Ding, Yufu Han

{"title":"血管性认知障碍患者MicroRNA-140-5p和胱抑素- c的表达及其临床价值","authors":"Huiyan Ding, Yufu Han","doi":"10.1080/17520363.2025.2468150","DOIUrl":null,"url":null,"abstract":"Background: Vascular cognitive impairment (VCI) is a cerebrovascular disease leading to mental decline. Appropriate biomarkers must be identified to facilitate the diagnosis of VCI. Therefore, we investigated changes in miR-140-5p and cystatin-C (Cys-C) expression in the serum of patients with VCI.Methods: The miR-140-5p or Cys-C serum expression levels were determined using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) or immunoturbidimetry. MMP-9 and IL-6 expression were detected in both groups. Correlations between serum-exhaled miR-140-5p or Cys-C and IL-6 or MMP-9 were analyzed using Pearson's method. A receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of miR-140-5p, Cys-C, and miR-140-5p combined with Cys-C for diagnosing VCI.Results: miR-140-5p and Cys-C serum levels were significantly upregulated in patients with VCI, and the increase was more pronounced in patients with vascular dementia (VaD). In addition, miR-140-5p and Cys-C positively correlated with increased IL-6 and MMP-9 expression. The ROC analysis showed that the combination of miR-140-5p and Cys-C demonstrated the AUC was 100.0% (sensitivity: 100%; specificity, 98.3%).Conclusion: The upregulation of miR-140-5p and Cys-C indicates that miR-140-5p and Cys-C may be related VCI development. The combined diagnosis of miR-140-5p has potential diagnostic value for diagnosis and screening of VCI.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-8"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MicroRNA-140-5p and cystatin-C expression in patients with vascular cognitive impairment and its clinical value.\",\"authors\":\"Huiyan Ding, Yufu Han\",\"doi\":\"10.1080/17520363.2025.2468150\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Vascular cognitive impairment (VCI) is a cerebrovascular disease leading to mental decline. Appropriate biomarkers must be identified to facilitate the diagnosis of VCI. Therefore, we investigated changes in miR-140-5p and cystatin-C (Cys-C) expression in the serum of patients with VCI.Methods: The miR-140-5p or Cys-C serum expression levels were determined using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) or immunoturbidimetry. MMP-9 and IL-6 expression were detected in both groups. Correlations between serum-exhaled miR-140-5p or Cys-C and IL-6 or MMP-9 were analyzed using Pearson's method. A receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of miR-140-5p, Cys-C, and miR-140-5p combined with Cys-C for diagnosing VCI.Results: miR-140-5p and Cys-C serum levels were significantly upregulated in patients with VCI, and the increase was more pronounced in patients with vascular dementia (VaD). In addition, miR-140-5p and Cys-C positively correlated with increased IL-6 and MMP-9 expression. The ROC analysis showed that the combination of miR-140-5p and Cys-C demonstrated the AUC was 100.0% (sensitivity: 100%; specificity, 98.3%).Conclusion: The upregulation of miR-140-5p and Cys-C indicates that miR-140-5p and Cys-C may be related VCI development. The combined diagnosis of miR-140-5p has potential diagnostic value for diagnosis and screening of VCI.\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"1-8\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2468150\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2468150","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

背景：血管性认知障碍（VCI）是一种导致智力下降的脑血管疾病。必须确定适当的生物标志物以促进VCI的诊断。因此，我们研究了VCI患者血清中miR-140-5p和胱抑素- c （cyys - c）表达的变化。方法：采用实时定量逆转录聚合酶链式反应（qRT-PCR）或免疫比浊法检测miR-140-5p或Cys-C血清表达水平。两组均检测MMP-9、IL-6的表达。采用Pearson方法分析血清呼出miR-140-5p或Cys-C与IL-6或MMP-9的相关性。采用受试者工作特征（ROC）曲线评价miR-140-5p、Cys-C以及miR-140-5p联合Cys-C对VCI的诊断价值。结果：miR-140-5p和Cys-C血清水平在VCI患者中显著上调，且在血管性痴呆（VaD）患者中升高更为明显。此外，miR-140-5p和Cys-C与IL-6和MMP-9表达升高呈正相关。ROC分析显示，miR-140-5p与Cys-C联合使用显示AUC为100.0%(灵敏度：100%；特异性,98.3%)。结论：miR-140-5p和Cys-C的上调提示miR-140-5p和Cys-C可能与VCI的发展有关。联合诊断miR-140-5p对VCI的诊断和筛查具有潜在的诊断价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

MicroRNA-140-5p and cystatin-C expression in patients with vascular cognitive impairment and its clinical value.

Background: Vascular cognitive impairment (VCI) is a cerebrovascular disease leading to mental decline. Appropriate biomarkers must be identified to facilitate the diagnosis of VCI. Therefore, we investigated changes in miR-140-5p and cystatin-C (Cys-C) expression in the serum of patients with VCI.

Methods: The miR-140-5p or Cys-C serum expression levels were determined using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) or immunoturbidimetry. MMP-9 and IL-6 expression were detected in both groups. Correlations between serum-exhaled miR-140-5p or Cys-C and IL-6 or MMP-9 were analyzed using Pearson's method. A receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of miR-140-5p, Cys-C, and miR-140-5p combined with Cys-C for diagnosing VCI.

Results: miR-140-5p and Cys-C serum levels were significantly upregulated in patients with VCI, and the increase was more pronounced in patients with vascular dementia (VaD). In addition, miR-140-5p and Cys-C positively correlated with increased IL-6 and MMP-9 expression. The ROC analysis showed that the combination of miR-140-5p and Cys-C demonstrated the AUC was 100.0% (sensitivity: 100%; specificity, 98.3%).

Conclusion: The upregulation of miR-140-5p and Cys-C indicates that miR-140-5p and Cys-C may be related VCI development. The combined diagnosis of miR-140-5p has potential diagnostic value for diagnosis and screening of VCI.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.